Update on vaccine-derived polioviruses — Worldwide, January 2014–March 2015

Morbidity and Mortality Weekly Report

Volumn 64, Issue 23, 2015, Pages 640-646

  Diop, Ousmane M ^a   Burns, Cara C ^b   Sutter, Roland W ^a   Wassilak, Steven G ^c   Kew, Olen M ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; SEWAGE;

ADULT; CHILD; CLASSIFICATION; EPIDEMIC; FEMALE; HEALTH; HUMAN; IMMUNOCOMPROMISED PATIENT; INFANT; ISOLATION AND PURIFICATION; MALE; NEWBORN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; SEROTYPING; SEWAGE; STATISTICS AND NUMERICAL DATA; VIROLOGY;

ADULT; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; GLOBAL HEALTH; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFANT, NEWBORN; MALE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; SEROTYPING; SEWAGE; VACCINES, ATTENUATED;

EID: 84931826865     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Hagan JE, Wassilak SGF, Craig AS, et al. Progress toward polio eradication—worldwide, 2014‒2015. MMWR Morb Mortal Wkly Rep 2015;64:527–31.
2. Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine—live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Sixth ed. London, England: W.B. Saunders; 2013:598–645.
3. Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014;210(Suppl 1):S380–9.
4. Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis 2014;210(Suppl 1):S283–93.
5. Diop OM, Burns CC, Wassilak SG, Kew OM. Update on vaccine-derived polioviruses—worldwide, July 2012–December 2013. MMWR Morb Mortal Wkly Rep 2014;63:242–8.
6. Global Polio Eradication Initiative. Polio eradication and endgame strategic plan (2013–2018). Available at http://www. polioeradication.org/portals/0/document/resources/strategywork/ endgamestratplan_20130414_eng.pdf.
7. Kilpatrick DR, Ching K, Iber J, et al. Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR. J Virol Methods 2014;197:25–8.
8. Burns CC, Shaw J, Jorba J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol 2013;87:4907–22.
9. Li L, Ivanova O, Driss N, et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J Infect Dis 2014;210(Suppl 1):S368–72.
10. Rhoden E, Liu HM, Wang-Chern SW, Oberste MS. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds. Antiviral Res 2013;98:186–91.